153 related articles for article (PubMed ID: 12820406)
1. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.
Hua J; Sheng Y; Pinney KG; Garner CM; Kane RR; Prezioso JA; Pettit GR; Chaplin DJ; Edvardsen K
Anticancer Res; 2003; 23(2B):1433-40. PubMed ID: 12820406
[TBL] [Abstract][Full Text] [Related]
2. Alterations in vascular architecture and permeability following OXi4503 treatment.
Chan LS; Malcontenti-Wilson C; Muralidharan V; Christophi C
Anticancer Drugs; 2008 Jan; 19(1):17-22. PubMed ID: 18043126
[TBL] [Abstract][Full Text] [Related]
3. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.
Hokland SL; Horsman MR
Int J Hyperthermia; 2007 Nov; 23(7):599-606. PubMed ID: 18038290
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
Siemann DW; Shi W
Anticancer Res; 2008; 28(4B):2027-31. PubMed ID: 18751370
[TBL] [Abstract][Full Text] [Related]
5. cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion.
Durrant D; Corwin F; Simoni D; Zhao M; Rudek MA; Salloum FN; Kukreja RC; Fatouros PP; Lee RM
Cancer Chemother Pharmacol; 2009 Jan; 63(2):191-200. PubMed ID: 18365199
[TBL] [Abstract][Full Text] [Related]
6. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo.
Burns CJ; Fantino E; Powell AK; Shnyder SD; Cooper PA; Nelson S; Christophi C; Malcontenti-Wilson C; Dubljevic V; Harte MF; Joffe M; Phillips ID; Segal D; Wilks AF; Smith GD
J Pharmacol Exp Ther; 2011 Dec; 339(3):799-806. PubMed ID: 21917561
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
Patterson DM; Zweifel M; Middleton MR; Price PM; Folkes LK; Stratford MR; Ross P; Halford S; Peters J; Balkissoon J; Chaplin DJ; Padhani AR; Rustin GJ
Clin Cancer Res; 2012 Mar; 18(5):1415-25. PubMed ID: 22235096
[TBL] [Abstract][Full Text] [Related]
8. Treatment of rodent liver tumor with combretastatin a4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology.
Wang H; Sun X; Chen F; De Keyzer F; Yu J; Landuyt W; Vandecaveye V; Peeters R; Bosmans H; Hermans R; Marchal G; Ni Y
Invest Radiol; 2009 Jan; 44(1):44-53. PubMed ID: 19034028
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours.
Dalal S; Burchill SA
Eur J Cancer; 2009 Mar; 45(4):713-22. PubMed ID: 19136249
[TBL] [Abstract][Full Text] [Related]
11. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503.
Rice L; Pampo C; Lepler S; Rojiani AM; Siemann DW
Microvasc Res; 2011 Jan; 81(1):44-51. PubMed ID: 20974154
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin inhibits hepatectomy-induced stimulation of metastatic tumor growth by reduction of angiogenesis, microvascular blood perfusion, and tumor cell proliferation.
Rupertus K; Dahlem C; Menger MD; Schilling MK; Kollmar O
Ann Surg Oncol; 2009 Sep; 16(9):2629-37. PubMed ID: 19551445
[TBL] [Abstract][Full Text] [Related]
13. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
[TBL] [Abstract][Full Text] [Related]
14. Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
Nielsen T; Bentzen L; Pedersen M; Tramm T; Rijken PF; Bussink J; Horsman MR; Østergaard L
Clin Cancer Res; 2012 Dec; 18(23):6469-77. PubMed ID: 23071260
[TBL] [Abstract][Full Text] [Related]
15. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
[TBL] [Abstract][Full Text] [Related]
16. Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents.
Horsman MR; Wittenborn TR; Nielsen PS; Elming PB
Int J Mol Sci; 2020 Jul; 21(13):. PubMed ID: 32640548
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of the vascular-disrupting agent ZD6126 in a murine renal cell carcinoma model.
Medinger M; Esser N; Soltau J; Lehmann KM; Konerding MA; Wolloscheck T; Ryan AJ; Drevs J
Int J Oncol; 2011 Feb; 38(2):455-64. PubMed ID: 21152862
[TBL] [Abstract][Full Text] [Related]
18. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
[TBL] [Abstract][Full Text] [Related]
19. Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
Stratford MR; Folkes LK
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(25):2673-6. PubMed ID: 21820978
[TBL] [Abstract][Full Text] [Related]
20. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]